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study question: The precise delineation of the research phase is a recurrent subject of debate: When is the evidence base firm enough to
decide that a new technology or treatment no longer needs to be regarded as ‘experimental’?
summary answer: We propose a framework that distinguishes between three instead of two types of treatment and describes a con-
tinuum from experimental over innovative to established treatment, offering a tool meant to facilitate decision-making about the introduction
of new technologies in the clinic.
what is known already: Traditionally, guidelines from medical societies on the notion of ‘experimental treatment’ depart from a
dichotomy between experimental and established treatment. However, in the field of reproductive medicine, there are several problems with
a dichotomous framework. First, it does not offer an adequate account of the reality in the clinic. Secondly, this view may bring about several nega-
tive effects for the patient, such as techniques being considered established too early, holding risks unknown to patients. A further drawback of the
dichotomy is that if a technique is no longer considered experimental, centres offering the technique may no longer consider it useful gathering and
critically examining (follow-up) data.
study design, size, duration: The framework and scoring tool were developed over several phases during which the authors oper-
ated as a consensus group of experts.
participants/materials, setting, methods: The scoring tool reflects the continuous progression of a new procedure from
experimental through innovative to established. For this evolution, four criteria were considered relevant. The first (efficacy) is a categorical cri-
terion (pass/fail). The other three criteria (safety, procedural reliability and transparency and effectiveness) are ordinal in nature. Thresholds have
been introduced for all four criteria to avoid that a technology scoring high on procedure and effectiveness but extremely low on safety could move
to the next level because of a sufficiently high overall score.
main results and the role of chance: Only treatments that are rated above the thresholds for all four criteria could be con-
sidered at least innovative treatments. When they score 4 or higher on the last three criteria, they are considered established treatments.
limitations, reasons for caution: Knowledge about the procedures or techniques under discussion is essential in order to use
the tool.
wider implications of the findings: The tool is designed to be used on a macro-level (e.g. by professional societies) although
it could also be valuable in the local setting. Both the framework and the tool can bring more clarity on the notion of ‘experimental treatment’,
especially with regard to how to decide when a specific technology or treatment falls in this category and when it can move into one of the other
categories.
†ESHRE pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE.
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Introduction
In the rapidly evolving field of reproductive medicine, the introduction of
new technologies or treatments is common practice. Ideally, this intro-
duction is preceded by scientific research into the efficacy and the
safety of the intervention. During this research phase any clinical applica-
tion of the technique would be considered experimental, meaning that it
should only be offered in a research setting and with approval of a medical
research ethics committee. However, the precise delineation of this re-
search phase is a recurrent subject of debate. When is the evidence base
firm enough to decide that a new technology or treatment no longer
needs to be regarded as ‘experimental’? Obviously, this is not just a se-
mantic debate, as much will depend on this label not just in terms of
how patients should be informed and counselled, but also in terms of or-
ganizational challenges and funding opportunities. A recent instance of
this debate turned on whether oocyte vitrification (a new technology
which makes it possible to effectively cryopreserve human oocytes)
should still be regarded as experimental or whether enough is known
about its efficacy and safety to lift this label and allow the technology to
be offered to patients as established treatment (Noyes et al., 2010;
Gosden, 2011; ESHRE Task Force on Ethics and Law, 2012). This
debate occasioned ESHRE’s Executive Committee to flag the need for
more clarity on the notion of ‘experimental treatment’, especially with
regard to how to decide up to what point a specific technology or treat-
ment needs to be regarded as falling in this category. The special interests
groups ‘Safety & Quality in Assisted Reproductive Technology’ and
‘Ethics & Law’ have considered this issue and drawn up the present
document.
In 2008, the American Society for Reproductive Medicine (ASRM) had
defined ‘experimental procedures’ as follows:
A procedure for the treatment of infertility is considered experimental until
there is adequate scientific evidence of safety and efficacy from appropriately
designed, peer-reviewed, published studies by different investigator groups
(ASRM, 2008).
In their 2009 and 2013 revision, the ASRM specified this level of adequate
scientific evidence required to lift the label of ‘experimental’ for new pro-
cedures (ASRM, 2009; ASRM, 2013). In the 2013 paper it was described
as ‘the published medical evidence regarding their risks, benefits, and
overall safety and efficacy is sufficient to regard them as established
medical practice’ (ASRM, 2013, p. 1197). According to this statement,
procedures are thus either considered established medical practice or
experimental; the latter requiring specific review of an Institutional
Review Board (ASRM, 2008).
In a recent statement replacing the recommendations on ovarian
tissue and oocyte cryopreservation issued in 2008, the Practice Commit-
tees of the ASRM and the Society for Reproductive Technology (SART)
have announced that oocyte vitrification is no longer to be considered
experimental (ASRM and SART, 2013). It is stated that there is sufficient
evidence on the safety and efficacy of egg freezing in order to remove the
label ‘experimental’.
The ASRM statements depart from a dichotomy between experimen-
tal and established treatment. However, there are several problems with
such aconceptual framework. First, it does not offeran adequate account
of the reality in the clinic. Many fertility centres offer treatments to
patients that are neither considered established medical treatment,
nor regarded as experimental. Secondly, this view may bring about
several negative effects for the patient. On the one hand, considering
all procedures that are not yet established as experimental would
imply that these procedures can only be performed with the specific
review of a medical research ethics committee. As this may impact
local availability, this could leave patients in the cold waiting for a treat-
ment they could benefit from. On the other hand, the opposite may
also be the case: techniques that are considered established too early,
may sometimes hold risks unknown to patients. For instance, patients
undergoing assisted reproduction techniques (IVF) with preimplantation
genetic screening a decade ago may have been exposed to a technology
that lowered rather than enhanced their chances of pregnancy (Geraedts
and De Wert, 2009). A further drawback of the dichotomy is that if a
technique is no longer considered experimental, centres offering the
technique may no longer feel the obligation to gather and critically
examine (follow-up) data about their patients, which holds risks on long-
term safety of patients and children.
In this paper, we offer an alternative conceptual framework as well as a
tool meant to facilitate decision-making about the introduction of new
technologies in the clinic. The framework that we propose here distin-
guishes between three instead of two types of treatment and describes
a continuum from experimental over innovative to established treatment.
It should be noted that the use of the term ‘innovative’ in our proposed
framework diverges from how this label is sometimes used in the litera-
ture, namely to identify a category of innovations that have not (yet) been
subjected to scientific research (Dondorp and de Wert, 2011). For in-
stance, this is how, in a recent document of the American College of
Obstetrics and Gynecology (ACOG), a distinction is made between
formal research (experimental treatment) and practice adaptions by in-
dividual practitioners aimed at benefitting their patients (innovative treat-
ment). The ACOG stresses that a practitioner should move such
‘innovative treatment’ into formal research ‘if the innovation represents
a significant departure from standard practice, if the innovation carries
unknown or potentially significant risks, or if the practitioner’s goal is
to use data from the innovation to produce generalizable knowledge’
(ACOG, 2006, p.1589).
Whereas in this understanding, ‘innovative treatment’ refers to a
phase that may precede the formal research phase of ‘experimental’
treatment, in our proposal it refers to an intermediate phase between
‘experimental’ and ‘established treatment’.
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Materials and Method
The conceptual framework and the scoring tool presented in this paper were
developed over several phases during which the authors operated as a con-
sensus group of experts. During the first meeting, the conceptual framework
was set up and criteria for the different types of treatment were defined. In a
second meeting, the framework was refined and a preliminary version of the
scoring tool was outlined. Next, draft versions of the scoring sheet and
scoring key were developed by the first two authors and finalized by consen-
sus in a third meeting.
The scoring tool reflects the continuous progression of a new procedure
from experimental through innovative to established. For this evolution, four
criteria were considered relevant. The first (efficacy) is a categorical criterion
(pass/fail). The other three criteria (safety, procedural reliability and trans-
parency and effectiveness) are ordinal in nature. Thresholds have been intro-
duced for all four criteria to avoid that a technology scoring high on procedure
and effectiveness but extremely low on safety could move to the next level
because of a sufficiently high overall score.
Results
From experimental to established:
three categories of treatment
In our proposal, a procedure is to be viewed experimental, innovative or
established based on the four criteria described above.
Experimental treatment
A new procedure can be offered to patients in an experimental design aimed
at showing proof of principle (efficacy), short-term safety and/or effective-
ness. Providing an experimental treatment requires a commitment to
gather evidence regarding safety (for both patient and embryo) and effective-
ness. Preferably, there should be studies showing that the experimental treat-
ment is safe in animals. Treatments involving laboratory procedures can be
offered when there is at least clinical embryology data that indicate normal
cleavage, embryo morphology and blastocyst formation. Experimental treat-
ment should always be embedded in a research setting, in which it is offered
to a selected and limited patient cohort. This requires the approval of a local
ethics committee, and informed consent of the patient. Patients should be
clearly and neutrally informed of the experimental status and should
receive information about (the lack of knowledge about) possible risks, alter-
native treatments etc.
Innovative treatment
An intervention can be considered innovative treatment when data from
experimental treatment, although still limited: (i) have shown proof of prin-
ciple (efficacy); (ii) are reassuring both in terms of safety (in comparison to
children conceived by standard treatment, e.g. regular IVF) and effectiveness,
(iii) are based on a procedure specified in sufficient detail and with limited
technical variability between separate studies. Furthermore, these data
must have been (a) obtained in studies with sound methodologies, and
(b) published in peer-reviewed journals.
Innovative treatment requires that all conditions applying to experimental
treatment have been fulfilled, next to a number of additional conditions. Pref-
erably, the safety of a new laboratory procedure has been shown in studies
reporting on its use in animals as well as preclinical data indicating normal
cleavage, embryo morphology and blastocyst formation in humans. Further-
more, there should be reassuring data on short-term safety, referring to the
patients undergoing the procedure as well as to any children born as a result.
These data should be based on experiments with sufficient statistical power.
If possible, studies should have been conducted aimed at demonstrating
effectiveness by comparing the new technology with standard treatment.
For a treatment to move from innovative to established, the level of evidence
required should be higher (see below).
Patients to whom innovative treatment is offered should be provided with
clear information about the fact that although the treatment is no longer con-
sidered experimental (meaning that there are some data indicating short-
term safety and effectiveness of the treatment), the body of evidence is still
limited and especially data on long-term effects are lacking. In contrast to
experimental treatment, no specific approval of a local ethics committee is
needed in order to offer innovative treatment to patients.
Providing innovative treatment implies a commitment to gather further
evidence about mid-term safety and effectiveness on all patients to whom
the treatment is offered and for as long as the intervention is not considered
established treatment. The data gathered by the centre should be made avail-
able to the scientific community in the form of peer-reviewed publications,
regardless of the success of the treatment: not withholding results that
point to a negative outcome or that turn out to be inconclusive.
Centres should systematically and uniformly collect data on procedures and
outcomes. Moreover, follow-up studies monitoring the health of patients and
children should still be conducted in order to gain more evidence about the
longer term safety of the procedure. This of course requires a research proto-
col, ethics committee approval and informed consent of research subjects.
Established treatment
A treatment is considered established or standard therapy when multi-
centred data are published in peer-reviewed journals, on the basis of which
it is regarded as a safe and effective therapy. Ideally, this should be based
on prospective randomized trials. Established procedures are performed
according to a standard and validated protocol.
However, follow-up is still required in order to monitor long-term (ideally
transgenerational) health effects, including aspects such as fertility, oncology
and mental health. Once a treatment is offered, it is the responsibility of the
centre to systematically collect treatment and outcome data that provide a
basis for such continued and long-term evaluation. Moreover, clinics
should always be prepared to invalidate treatment when proved problematic
(in terms of safety or effectiveness).
The path to established therapy: a tool to
situate a procedure along the continuum
In order to situate a treatment on the continuum from experimental through
innovative to established, it is important to consider the four criteria based on
(at least some reports of) research published in peer-reviewed journals:
efficacy, safety, procedural reliability and transparency and effectiveness.
Figure 1 presents a sequential four-criterion tool to assess specific treatments
or technologies. For each of the criteria a threshold is indicated. Once a treat-
ment scoresbelow the threshold forone of the criteria, it cannot be viewed as
innovative even though it would score high on subsequent criteria. Only
treatments that are rated above the thresholds for all four criteria could be
considered at least innovative treatments. When they score 4 or higher on
the last three criteria, they are considered established treatments.
In an ideal situation, the sequence of the proposed categories could be
viewed as divisions on a continuum, with procedures moving from experi-
mental to established over time. In this way, innovative treatments would
be preceded by at least a limited experimental phase. The further a proced-
ure moves on the continuum, the more will be known about its safety and
effectiveness while the procedural variability will decrease.
In order to situate a treatment on the continuum, it is important to con-
sider the four criteria based on (at least some reports of) research published
in peer-reviewed journals. Each of the criteria should be scored according to
the scoring key outlined in Table I. In order to do so, a significant level of
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knowledge is required about the treatment or procedure (including recent
literature on the topic).
Given that our account of three phases is an ideal model, the continuum
should be treated in a flexible way, so as to realistically reflect the
development of techniques in practice. For instance, it is possible that, for
a certain procedure, there was no distinct experimental phase. Sometimes,
practice rather than research has led to sufficient data on which a decision
can be made to regard a new technology or treatment as innovative rather
Figure 1 Sequential four-criterion assessment tool to consider the transition of a treatment from experimental through innovative to established.
*Numbers represent the scores at either end of the threshold for each of the four criteria for the first transition (from experimental to innovative) and
for each of the three last criteria for the second transition (from innovative to established).
.............................................................................................................................................................................................
Table 1 Scoring key used in the tool for distinguishing between treatments.
Criterion Definition Scoring
Efficacy Proof of principle 0: No proof of principle has been demonstrated
1*: Proof of principle has been demonstrated
Safety The safety of the procedure, referring
to the patients as well as the future children
1: Considered safe in animals
2: Reassuring preclinical data
3*: Reassuring short-term data in human (up to at least 3 months post-delivery) in
peer-reviewed journals
4**: Reassuring mid-term data in human (up to at least 5 years post-delivery and including
data on psychological development) in peer-reviewed journals
5: Reassuring long-term data in human (up to at least 25 years post-delivery, including data
on psychological development and preferably on fertility) in peer-reviewed journals
Procedure Procedural reliability and transparency: the
similarity or variability of the procedure in
different laboratories and the potential for
implementation by other centres
1: No procedure has been described yet, or the procedure varies enormously between laboratories
2*: Technical performance of the procedure is highly variable between laboratories
3: Technical performance of the procedure is relatively comparable between laboratories
4**: Technical performance of the procedure is highly comparable between laboratories
5: Throughout different centres, the procedure is considered a routine technique with
common technical performance
Effectiveness The likelihood of producing the desired
outcome compared with outcome of
conventional, established ART techniques
1: Completely unknown, doubtful or extremely low
2*: Low
3: Reasonable
4: Acceptable but not as high as established ART treatment
5**: As high or higher than established ART techniques
An example of an established treatment is IVF.
ART, assisted reproduction techniques.
*Threshold for innovative treatment.
**Threshold to move from innovative to established treatment for the criteria ‘safety’, ‘procedure’ and ‘effectiveness’. ‘Efficacy’ is an all-or-nothing criterion that only has one threshold
(1, to move from experimental to innovative treatment).
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than experimental. The introduction of oocyte vitrification is an example of
this. Also, an innovative treatment could be (and should be) invalidated
when found unsafe, ineffective or otherwise problematic. In that case, it
would not move forward along the continuum.
Conclusion
Clarifying the boundaries between research and treatment and identify-
ing the distinctions and gradations between them can benefit patients
both directly (by way of safeguarding the possibility of offering chances
as well as minimizing the exposure to risks and negative effects) and indir-
ectly (through the advancement of medicine and the contribution of data
to a growing body of knowledge).
The framework offered in this paper is new in that it includes acategory
of ‘innovative treatment’ as intermediate between ‘experimental’ and
‘established’. In addition, we provide a tool to facilitate the discussion
and reach an agreement about the classification of treatments for infer-
tility. The tool is designed to be used on a macro-level (e.g. by profession-
al societies) although it could also be valuable in the local setting.
Of course, experts may vary in their evaluation of specific techniques.
This is not necessarily problematic, it would rather indicate a need to
debate the matter and would show that a narrow (or dichotomous) clas-
sification of techniques is not desirable. Knowledge about the proce-
dures or techniques under discussion is essential in order to use the
tool. Therefore, it is recommended to use the tool by assembling a
group of recognized experts on a specific topic and have them scoring
the technique. Alternatively, its application could be based on a system-
atic review of the literature.
Both the framework and the tool can bring more clarity on the notion
of ‘experimental treatment’, especially with regard to how to decide
when a specific technology or treatment falls in this category and when
it can move into one of the other categories.
Recommendations
Experimental treatment
(1) Centres offering experimental treatment should do so only after ap-
proval by a medical research ethics committee.
Innovative treatment
(1) Only centres with expertise about the procedure should offer in-
novative treatment to their patients.
(2) Centres offering innovative treatment should make a commitment
to closely monitor their practice by conducting follow-up studies
with the purpose of publishing the (positive and negative) results
in peer-reviewed journals. For these studies a formal approval of a
medical research ethics committee must be obtained.
(3) Patients interested in innovative treatment should be adequately
informed about all relevant aspects of the procedure and about
the status of the treatment. This means that patients should be
informed about the innovative character of the treatment meaning
that there is only limited information available about children born
after this procedure and data on long-term safety still need to be
gathered.
(4) Patients interested in innovative treatment should also be informed
about the centre’s commitment to monitor the practice. Before the
onset of treatment, these patients should also be asked for their
consent to be contacted in the future for follow-up studies.
(5) Centres offering innovative treatment should always be prepared to
stop treatment when there are signs of serious concern based on
their own studies or on published reports.
Established treatment
(1) Centres should take steps to facilitate a uniform data collection
(registries) with the aim of enabling studies to evaluate long-term
(including multigenerational) consequences.
(2) Clinics should always be prepared to stop treatment when proved
problematic (in terms of efficacy, safety or effectiveness).
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